ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)

Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*广东省人民医院; 广州医学院; 广州中医药大学; 华中科技大学; 南昌大学; 南方医科大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 中山大学; 重庆大学; 中国科学院研究生院; 1
Translational Lung Cancer Research2023-1DOI: 10.21037/tlcr-22-852
16阅读
引用收藏
分享

摘要

Background: Camrelizumab plus chemotherapy have been approved as standards for the treatment of advanced non-small cell lung cancer (NSCLC) patients based on two phase III trials. However, clinical trial results may not be representative of the general population, as clinical trials often have specific inclusion and exclusion criteria. Our research aims to investigate the real-world effectiveness and safety of camrelizumab in inoperable or advanced NSCLC patients.Methods: This multicenter retrospective observational study included inoperable or advanced pathologically confirmed NSCLC patients who received at least one dose of camrelizumab at 22 hospitals. Clinical and follow-up data of camrelizumab were collected retrospectively from the medical records. The primary outcome was the objective response rate (ORR) and secondary outcomes were disease control rate (DCR), 6-month progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Multivariate logistic and Cox regression analyses were applied to identify potential predictive factors of ORR and PFS, respectively.Results: Between July 2019 and March 2021, 336 patients were included. Adenocarcinoma was seen in 58.4% and stage IV disease in 69.3%. Twenty-nine (8.6%) had liver metastasis at baseline. Most patients received camrelizumab in the first-line setting (74.1%) and in combination with chemotherapy (60.7%). The ORR was 40.2% [95% confidence interval (CI): 34.9-45.6%] and DCR was 85.1% (95% CI: 81.3-88.9%), while the 6-month PFS and OS rates were 73.0% (95% CI: 67.1-78.0%) and 93.1% (95% CI: 89.8-95.4%), respectively. In multivariate analyses, liver metastasis [odds ratio (OR), 0.324; 95% CI: 0.115-0.915; P=0.033] and increasing lines of camrelizumab treatment (vs. first line, second line: OR, 0.347; 95% CI: 0.162-0.741; P=0.006; >= third line: OR, 0.126; 95% CI: 0.043-0.367; P<0.001) were negatively associated, while a longer duration of camrelizumab treatment was positively associated with ORR and PFS. TRAEs were recorded in 164 (48.8%) patients, without new safety signal.Conclusions: We conducted a comprehensive overview of the effectiveness and safety profile of camrelizumab in a broader NSCLC population in real world NSCLC patients, and subgroup analysis indicated the presence of liver metastasis was associated with worse outcomes.

学科与关键词

关键词
Non-small cell lung cancer (NSCLC)samrelizumabobservational studyreal-world
相关
加载中…
  • Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)
    Liu, Si-Yang; Chen, Qixun; Zhou, Chengzhi; Zhang, Huizhong; Li, Wen; Chen, Jianhua; Hu, Jian; Wu, Lin; Chen, Qunqing; Dai, Qiangsheng; Shan, Jian-Zhen; Xu, Fei; Liu, Si-Yang Maggie*; Wu, Yi-Long*Cancer Immunology, Immunotherapy, 2023, 72(7): 2257-2265.被引 3
  • Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study
    Pu, Xingxiang; Wang, QianZhi; Liu, Liyu; Chen, Bolin; Li, Kang; Zhou, Yu; Sheng, Zengmei; Liu, Ping; Tang, Yucheng; Xu, Li; Li, Jia; Kong, Yi; Xu, Fang; Xu, Yan; Wu, Lin*Cancer Medicine, 2023, 12(7): 7724-7733.被引 3
  • CamreliZumab Plus Carboplatin and PemetreXed as First-Line Treatment for Advanced NonsQuamous NSCLC: EXtended Follow-Up of CameL Phase 3 Trial
    Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, YongQian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, GuangyuJournal of Thoracic Oncology, 2023, 18(5): 628-639.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2023-01
卷期
第 12 卷, 第 1 期
页码
127-+
DOI
10.21037/tlcr-22-852
成果收录
SCIE

作者

  • X

    Xu, Chong-Rui (第一作者)

    guangdong prov peoples hosp

  • C

    Chen, Qixun

    univ chinese acad sci

查看全部 30 位作者收起作者
  • Z

    Zhou, Chengzhi

    1 · guangzhou med univ

  • W

    Wu, Lin

    2 · hunan canc hosp

  • L

    Li, Wen

    2 · zhejiang univ

  • Z

    Zhang, Huizhong

    sun yat sen univ

  • L

    Li, Yongsheng

    chongqing univ

  • X

    Xu, Fei

    1 · nanchang univ

  • X

    Xiong, Jianping

    1 · guangdong prov peoples hosp

  • W

    Wang, Qiming

    zhengzhou univ

  • Z

    Zhang, Haibo

    1 · 2 · guangzhou univ chinese med

  • J

    Jiang, Yuequan

    chongqing univ

  • Y

    Yin, Haitao

  • W

    Wu, Qingchen

    sun yat sen univ

  • D

    Dai, Qiangsheng

    1 · zhejiang univ

  • H

    Hu, Jian

    hunan canc hosp

  • C

    Chen, Jianhua

  • Z

    Zhang, Jian

    southern med univ

  • W

    Wu, Gang

    huazhong univ sci & technol

  • Y

    Yin, Jun

  • Z

    Zhao, Jianfu

    1

  • L

    Liu, Baogang

    harbin med univ

  • S

    Shan, Jianzhen

    1 · zhejiang univ

  • S

    Sheng, Liming

    univ chinese acad sci

  • C

    Chen, Qunqing

    southern med univ

  • H

    Han, Zhengxiang

    xuzhou med univ

  • S

    Shi, Huaqiu

    1 · gannan med univ

  • L

    Liu, Yimin

    sun yat sen univ

  • C

    Chen, Jun

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417